In summary, the mechanisms underlying lorlatinib-induced adaptive resistance in ALK-rearranged NSCLC rely on activation of EGFR signaling via endogenous HB-EGF stimulation, the feedback loop of which is induced by the JNK/c-Jun axis. The gene discussed is ALK; the disease is non-small cell lung carcinoma.